Prevalence of SARS-CoV-2 among high-risk populations in Lomé (Togo) in 2020
- PMID: 33166369
- PMCID: PMC7652308
- DOI: 10.1371/journal.pone.0242124
Prevalence of SARS-CoV-2 among high-risk populations in Lomé (Togo) in 2020
Abstract
Background: In December 2019, the COVID-19 outbreak began in China and quickly spread throughout the world and was reclassified as a pandemic in March 2020. The first case of COVID-19 was declared in Togo on March 5. Two months later, few data were available to describe the circulation of the new coronavirus in the country.
Objective: This survey aimed to estimate the prevalence of SARS-CoV-2 in high-risk populations in Lomé.
Materials and methods: From April 23, 2020, to May 8, 2020, we recruited a sample of participants from five sectors: health care, air transport, police, road transport and informal. We collected oropharyngeal swabs for direct detection through real-time reverse transcription polymerase chain reaction (rRT-PCR) and blood for antibody detection by serological tests. The overall prevalence (current and past) of infection was defined by positivity for both tests.
Results: A total of 955 participants with a median age of 36 (IQR 32-43) were included, and 71.6% (n = 684) were men. Approximately 22.1% (n = 212) were from the air transport sector, 20.5% (n = 196) were from the police sector, and 38.7% (n = 370) were from the health sector. Seven participants (0.7%, 95% CI: 0.3-1.6%) had a positive rRT-PCR test result at the time of recruitment, and nine (0.9%, 95% CI: 0.4-1.8%) were seropositive for IgM or IgG against SARS-CoV-2. We found an overall prevalence of 1.6% (n = 15), 95% CI: 0.9-2.6%.
Conclusion: The prevalence of SARS-CoV-2 infection among high-risk populations in Lomé was relatively low and could be explained by the various measures taken by the Togolese government. Therefore, we recommend targeted screening.
Conflict of interest statement
The authors have declared that no competing interests exist
Figures
Similar articles
-
COVID-19 and lombardy: TESTing the impact of the first wave of the pandemic.EBioMedicine. 2020 Nov;61:103069. doi: 10.1016/j.ebiom.2020.103069. Epub 2020 Oct 22. EBioMedicine. 2020. PMID: 33130396 Free PMC article.
-
Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019.PLoS One. 2020 Oct 9;15(10):e0240502. doi: 10.1371/journal.pone.0240502. eCollection 2020. PLoS One. 2020. PMID: 33035234 Free PMC article.
-
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.Lancet Infect Dis. 2020 May;20(5):565-574. doi: 10.1016/S1473-3099(20)30196-1. Epub 2020 Mar 23. Lancet Infect Dis. 2020. PMID: 32213337 Free PMC article.
-
Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients.PLoS One. 2020 Sep 8;15(9):e0236311. doi: 10.1371/journal.pone.0236311. eCollection 2020. PLoS One. 2020. PMID: 32898153 Free PMC article.
-
Epidemiology of SARS-CoV-2 antibodies among firefighters/paramedics of a US fire department: a cross-sectional study.Occup Environ Med. 2020 Dec;77(12):857-861. doi: 10.1136/oemed-2020-106676. Epub 2020 Aug 6. Occup Environ Med. 2020. PMID: 32764107
Cited by
-
Seroprevalence and risk factors for SARS-CoV-2 infection in middle-sized cities of Burkina Faso: A descriptive cross-sectional study.PLoS One. 2024 Aug 7;19(8):e0305850. doi: 10.1371/journal.pone.0305850. eCollection 2024. PLoS One. 2024. PMID: 39110710 Free PMC article.
-
Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.IJID Reg. 2022 Jun;3:117-125. doi: 10.1016/j.ijregi.2022.02.007. Epub 2022 Mar 5. IJID Reg. 2022. PMID: 35720135 Free PMC article.
-
Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study.Clin Infect Dis. 2022 Mar 23;74(6):1030-1038. doi: 10.1093/cid/ciab589. Clin Infect Dis. 2022. PMID: 34185847 Free PMC article.
-
SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.JAMA Netw Open. 2022 Oct 3;5(10):e2236053. doi: 10.1001/jamanetworkopen.2022.36053. JAMA Netw Open. 2022. PMID: 36219441 Free PMC article.
-
SARS-CoV-2 Seroprevalence in Those Utilizing Public Transportation or Working in the Transportation Industry: A Rapid Review.Int J Environ Res Public Health. 2022 Sep 15;19(18):11629. doi: 10.3390/ijerph191811629. Int J Environ Res Public Health. 2022. PMID: 36141897 Free PMC article. Review.
References
-
- World Health Organization (WHO), Health Emergencies Programmes. Weekly update on COVID-192–8 May 2020 [Internet]. 2020. [Cited 14/07/2020]. Available from: https://www.who.int/publications/m/item/weekly-update-on-covid-19—8-may-....
-
- World Health Organization, Regional Office for Africa (OMS/AFRO). Covid 19: Situation update for the WHO African region, 5 May 2020 [Internet]. 2020. [Cited 14/07/2020]. Available from: https://apps.who.int/iris/bitstream/handle/10665/331989/SITREP_COVID-19_....
-
- Richterich Peter. Severe underestimation of COVID-19 case numbers: effect of epidemic growth rate and test restrictions. medRxiv. 2020; 10.1101/2020.04.13.20064220 - DOI
-
- Lachmann A, Jagodnik KM, Giorgi FM, Ray F. Correcting under-reported COVID-19 case numbers: estimating the true scale of the pandemic. medRxiv. 2020; 2020.03.14.20036178. 10.1101/2020.03.14.20036178 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous